Wuhan Healthgen Biotechnology Corp. announced that it will issue 24,168,399 shares at a price of CNY 19.24 per share for gross proceeds of CNY 464,999,996.76 in its pre-IPO round of funding led by new investors Betta Pharmaceuticals Co., Ltd. for 20,010,395 shares on March 4, 2022. The transaction will also include participation from Hangzhou Beiming Equity Investment Fund Partnership Enterprise (L.P.), a fund managed by Hangzhou Beijia Investment Management Co., Ltd. for 4,158,004 shares.

The transaction has been approved in the 29th meeting of the third board of directors and the 23rd meeting of the third board of supervisors of Betta Pharmaceuticals Co., Ltd.